EUVIMEDObjevte EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY-NC 4.0

Nonavalent HPV vaccine to prevent recurrent anal or vulvar high‐grade squamous intraepithelial lesions ( VIVA trial): A randomized, double‐blind, placebo‐controlled trial

Helen C Stankiewicz Karita, Amalia S Magaret, David R Doody, Jeffrey T Schouten, Constance Mao, Warner K Huh, Verena S Grieco, Matthew A Seymour, Dana Varon, Kelly H Shrader, Long Fu Xi, Denise A Galloway and 2 more

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70366 ↗

At a glance

Randomisierte kontrollierte Studie in International Journal of Cancer, 2026. Written by Helen C Stankiewicz Karita and 13 co-authors. Institution: Department of Medicine, University of Washington, Seattle, Washington, DC, USA. Major MEDLINE topics: Papillomavirus Vaccines, Squamous Intraepithelial Lesions, Papillomavirus Infections, Vulvar Neoplasms. Cited 5 times so far (Crossref); 43 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: NCI NIH HHS, NIAID NIH HHS, National Cancer Institute.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

The nonavalent human papillomavirus (9vHPV) vaccine protects against HPV infection and high‐grade squamous intraepithelial lesions (HSIL) when administered prior to exposure, but evidence supporting its potential therapeutic benefit has been inconsistent. This randomized, double‐blind, placebo‐controlled trial evaluated whether the 9vHPV vaccine reduces recurrence of HSIL or HPV persistence in 27–69‐year‐old persons previously treated for anal or vulvar HSIL. Participants were HSIL‐free at enrollment and received 9vHPV or placebo at months 0, 2, and 6. High‐resolution anoscopy or vulvoscopy was performed at months 18 and 36, and anal or vulvar swabs were collected at months 0, 18, 24, and 36 for HPV DNA detection. The primary endpoints were HSIL recurrence and HPV persistence (≥2 consecutive positive swabs for the same 9vHPV‐type). Of 185 participants included in the intent‐to‐treat analysis, 91 received vaccine and 94 received placebo. The DSMB recommended early termination for futility. The 9vHPV vaccine was not more effective than placebo in preventing recurrent HSIL, with 16 HSIL among 9vHPV recipients versus 21 HSIL in placebo recipients (incidence 8.1 vs. 10.1/100 person‐years; p = .54). HPV persistence was 21% in vaccine versus 31% in placebo recipients ( p = .20). The 9vHPV vaccine delivered after treatment of anal or vulvar HSIL did not reduce HSIL recurrence or HPV detection. Our study underlines the importance of HPV vaccine administration prior to HPV exposure and the need for novel treatments for HSIL with high recurrence potential.

Subjects

MeSH terms (MEDLINE)

Papillomavirus VaccinesSquamous Intraepithelial LesionsPapillomavirus InfectionsVulvar NeoplasmsNeoplasm Recurrence, LocalHuman Papillomavirus VirusesAnus NeoplasmsHumansFemaleDouble-Blind MethodAdultAgedMiddle Aged

Author keywords

HPV vaccinationanal HSILhuman papillomavirusvulvar HSIL

Substances

Papillomavirus Vaccines

Authors and institutions

  • Department of Medicine, University of Washington, Seattle, Washington, DC, USA.
  • Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, DC, USA.
  • Department of Biostatistics, University of Washington, Seattle, Washington, DC, USA.
  • Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, DC, USA.
  • Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, DC, USA.
  • Department of Surgery, University of Washington, Seattle, Washington, DC, USA.

Funding

  • NCI NIH HHS
  • NIAID NIH HHS
  • National Cancer Institute

Cite

APA

Stankiewicz Karita, H. C., Magaret, A. S., Doody, D. R., Schouten, J. T., Mao, C., Huh, W. K., Grieco, V. S., Seymour, M. A., Varon, D., Shrader, K. H., Xi, L. F., Galloway, D. A., Wald, A., & Madeleine, M. M. (2026). Nonavalent HPV vaccine to prevent recurrent anal or vulvar high‐grade squamous intraepithelial lesions ( VIVA trial): A randomized, double‐blind, placebo‐controlled trial. International Journal of Cancer. https://doi.org/10.1002/ijc.70366

Vancouver

Stankiewicz Karita HC, Magaret AS, Doody DR, Schouten JT, Mao C, Huh WK, et al. Nonavalent HPV vaccine to prevent recurrent anal or vulvar high‐grade squamous intraepithelial lesions ( VIVA trial): A randomized, double‐blind, placebo‐controlled trial. International Journal of Cancer. 2026. doi:10.1002/ijc.70366

BibTeX
@article{StankiewiczKarita2026,
  author = {Stankiewicz Karita, Helen C and Magaret, Amalia S and Doody, David R and Schouten, Jeffrey T and Mao, Constance and Huh, Warner K and Grieco, Verena S and Seymour, Matthew A and Varon, Dana and Shrader, Kelly H and Xi, Long Fu and Galloway, Denise A and Wald, Anna and Madeleine, Margaret M},
  title = {Nonavalent HPV vaccine to prevent recurrent anal or vulvar high‐grade squamous intraepithelial lesions ( VIVA trial): A randomized, double‐blind, placebo‐controlled trial},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70366}
}
Start for free →